For decades, selective estrogen receptor modulators (SERMs), such as tamoxifen, were the most widely used hormonal therapy for HR-positive breast cancer (Baumann & Castiglione-Gertsch, 2007). The gene discussed is ESR1; the disease is breast carcinoma.